Mollica, V.; Santoni, M.; Matrana, M. R.; Basso, U.; De Giorgi, U.; Rizzo, A.; Maruzzo, M.; Marchetti, A.; Rosellini, M.; Bleve, S.; Maslov, D.; Tawagi, K.; Philon, E.; Blake, Z.; Massari, F., Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma, «TARGETED ONCOLOGY», 2022, 17, pp. 61 - 68 [articolo]
Santoni M.; Molina-Cerrillo J.; Myint Z.W.; Massari F.; Buchler T.; Buti S.; Matrana M.R.; De Giorgi U.; Rizzo M.; Zabalza I.O.; Galli L.; Zucali P.A.; Aurilio G.; Incorvaia L.; Bassanelli M.; Mammone G.; Salfi A.; Isella L.; Mollica V.; Grande E.; Porta C.; Battelli N., Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies, «TARGETED ONCOLOGY», 2022, 17, pp. 571 - 581 [articolo]
Ciccarese C.; Iacovelli R.; Buti S.; Primi F.; Astore S.; Massari F.; Ferrara M.G.; Palermo G.; Foschi N.; Iacovelli V.; Rossi E.; Schinzari G.; Bove P.; Bassi P.; Bria E.; Tortora G., Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?, «ANTICANCER RESEARCH», 2022, 42, pp. 1487 - 1493 [articolo]
Di Sciascio L.; Ambrosi F.; Franceschini T.; Giunchi F.; Franchini E.; Massari F.; Bianchi F.M.; Colecchia M.; Fiorentino M.; Ricci C., Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?, «PATHOLOGY RESEARCH AND PRACTICE», 2022, 234, Article number: 153937, pp. 153937 - 153937 [articolo]
Nigro M.C.; Mollica V.; Marchetti A.; Cheng M.; Rosellini M.; Montironi R.; Cheng L.; Massari F., Current androgen receptor antagonists under investigation for resistant prostate cancer, «EXPERT REVIEW OF ANTICANCER THERAPY», 2022, 22, pp. 191 - 202 [articolo]
Molina-Cerrillo J.; Santoni M.; Ruiz A.; Massari F.; Pozas J.; Ortego I.; Gomez V.; Grande E.; Alonso-Gordoa T., Epigenetics in advanced renal cell carcinoma: Potential new targets, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 180, Article number: 103857, pp. 103857 - 103866 [articolo]
Rizzo A.; Mollica V.; Massari F., Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis, «EUROPEAN UROLOGY FOCUS», 2022, 8, pp. 152 - 159 [articolo]
Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J., Genomics and Immunomics in the Treatment of Urothelial Carcinoma, «CURRENT ONCOLOGY», 2022, 29, pp. 3499 - 3518 [articolo]Open Access
Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F., Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2022, 7, pp. 131 - 149 [articolo]
Rebuzzi S.E.; Rescigno P.; Catalano F.; Mollica V.; Vogl U.M.; Marandino L.; Massari F.; Mestre R.P.; Zanardi E.; Signori A.; Buti S.; Bauckneht M.; Gillessen S.; Banna G.L.; Fornarini G., Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives, «CANCERS», 2022, 14, Article number: 1245, pp. 1 - 16 [articolo]Open Access
Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F., Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis, «FUTURE ONCOLOGY», 2022, 18, pp. 739 - 748 [articolo]
Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fiorentino M.; Massari F., Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2022, 22, pp. 997 - 1008 [articolo]
Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F., Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2022, 18, pp. 235 - 240 [articolo]
Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 371 - 378 [articolo]
Santoni M.; Aurilio G.; Massari F.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Zabalza I.O.; Mollica V.; Rizzo A.; Battelli N.; Porta C., Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 285 - 295 [articolo]
